{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T10:00:31Z","timestamp":1790503231771,"version":"4.1.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.steroids.2013.01.008","type":"journal-article","created":{"date-parts":[[2013,2,8]],"date-time":"2013-02-08T23:17:14Z","timestamp":1360365434000},"page":"530-537","source":"Crossref","is-referenced-by-count":56,"title":["New insights on the role of hormonal therapy in ovarian cancer"],"prefix":"10.1016","volume":"78","author":[{"given":"Fiona","family":"Simpkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Garcia-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Slingerland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.steroids.2013.01.008_b0005","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s11864-002-0059-3","article-title":"Epithelial ovarian cancer","volume":"3","author":"Hensley","year":"2002","journal-title":"Curr Treat Options Oncol"},{"issue":"9","key":"10.1016\/j.steroids.2013.01.008_b0010","first-page":"723","article-title":"Recurrent ovarian cancer","volume":"3","author":"Tummala","year":"2005","journal-title":"Clin Adv Hematol Oncol"},{"issue":"2","key":"10.1016\/j.steroids.2013.01.008_b0015","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1677\/erc.0.0070085","article-title":"Hormone therapy in epithelial ovarian cancer","volume":"7","author":"Makar","year":"2000","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.steroids.2013.01.008_b0020","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1385\/ENDO:26:3:297","article-title":"Ovarian aging and the perimenopausal transition: the paradox of endogenous ovarian hyperstimulation","volume":"26","author":"Prior","year":"2005","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.steroids.2013.01.008_b0025","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ygyno.2005.06.052","article-title":"Age-specific ovarian cancer incidence rate patterns in the United States","volume":"99","author":"Quirk","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"9574","key":"10.1016\/j.steroids.2013.01.008_b0030","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S0140-6736(07)60534-0","article-title":"Ovarian cancer and hormone replacement therapy in the Million Women Study","volume":"369","author":"Beral","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.steroids.2013.01.008_b0035","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/cncr.23956","article-title":"Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin","volume":"115","author":"Pearce","year":"2009","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.steroids.2013.01.008_b0040","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1001\/jama.285.11.1460","article-title":"Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women","volume":"285","author":"Rodriguez","year":"2001","journal-title":"J Am Med Assoc"},{"issue":"7","key":"10.1016\/j.steroids.2013.01.008_b0045","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jnci\/94.7.497","article-title":"Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women","volume":"94","author":"Riman","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.steroids.2013.01.008_b0050","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jama.288.3.334","article-title":"Menopausal hormone replacement therapy and risk of ovarian cancer","volume":"288","author":"Lacey","year":"2002","journal-title":"J Am Med Assoc"},{"issue":"20","key":"10.1016\/j.steroids.2013.01.008_b0055","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1001\/archinte.164.20.2253","article-title":"Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer","volume":"164","author":"Glud","year":"2004","journal-title":"Arch Intern Med"},{"issue":"3\u20134","key":"10.1016\/j.steroids.2013.01.008_b0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0960-0760(94)90019-1","article-title":"The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines","volume":"50","author":"Langdon","year":"1994","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"10.1016\/j.steroids.2013.01.008_b0065","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/0959-8049(94)90545-2","article-title":"Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model","volume":"30A","author":"Langdon","year":"1994","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.steroids.2013.01.008_b0070","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1158\/1078-0432.CCR-08-2525","article-title":"Estrous cycle modulates ovarian carcinoma growth","volume":"15","author":"Armaiz-Pena","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.steroids.2013.01.008_b0645","doi-asserted-by":"crossref","first-page":"5911","DOI":"10.1158\/1078-0432.CCR-12-1257","article-title":"Src inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo","volume":"18","author":"Simpkins","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"23","key":"10.1016\/j.steroids.2013.01.008_b0080","first-page":"5367","article-title":"Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis","volume":"58","author":"Pujol","year":"1998","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.steroids.2013.01.008_b0085","doi-asserted-by":"crossref","first-page":"5861","DOI":"10.1158\/0008-5472.CAN-04-0552","article-title":"Involvement of estrogen receptor beta in ovarian carcinogenesis","volume":"64","author":"Bardin","year":"2004","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.steroids.2013.01.008_b0090","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1677\/erc.1.01039","article-title":"Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen","volume":"12","author":"O\u2019Donnell","year":"2005","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.steroids.2013.01.008_b0095","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1124\/mi.3.5.281","article-title":"Estrogen signaling: a subtle balance between ER alpha and ER beta","volume":"3","author":"Matthews","year":"2003","journal-title":"Mol Interv"},{"issue":"3","key":"10.1016\/j.steroids.2013.01.008_b0100","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1210\/jc.83.3.1025","article-title":"Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues","volume":"83","author":"Brandenberger","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.steroids.2013.01.008_b0105","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/molehr\/4.8.811","article-title":"Expression of oestrogen receptor alpha and beta in cultured human ovarian surface epithelial cells","volume":"4","author":"Hillier","year":"1998","journal-title":"Mol Hum Reprod"},{"issue":"3","key":"10.1016\/j.steroids.2013.01.008_b0110","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0029-7844(00)00917-0","article-title":"Absence of estrogen receptor-beta expression in metastatic ovarian cancer","volume":"96","author":"Rutherford","year":"2000","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.steroids.2013.01.008_b0605","doi-asserted-by":"crossref","DOI":"10.1097\/00000478-200105000-00016","article-title":"Absence of estrogen receptor-[alpha] expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma","volume":"25","author":"Fujimura","year":"2001","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.steroids.2013.01.008_b0120","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1067\/mob.2003.328","article-title":"Estrogen and progesterone receptor subtype expression in normal and malignant ovarian epithelial cell cultures","volume":"189","author":"Li","year":"2003","journal-title":"Am J Obstet Gynecol"},{"issue":"1\u20132","key":"10.1016\/j.steroids.2013.01.008_b0125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.mce.2004.02.020","article-title":"Estrogen and progesterone receptors in ovarian epithelial tumors","volume":"221","author":"Lindgren","year":"2004","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"10.1016\/j.steroids.2013.01.008_b0130","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/pros.10171","article-title":"Differential expression of the estrogen receptor beta (ER-beta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma","volume":"54","author":"Fixemer","year":"2003","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.steroids.2013.01.008_b0135","first-page":"245","article-title":"Selective loss of estrogen receptor beta in malignant human colon","volume":"60","author":"Foley","year":"2000","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.steroids.2013.01.008_b0140","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1024406223619","article-title":"Expression of estrogen receptor-beta in normal mammary and tumor tissues: is it protective in breast carcinogenesis?","volume":"80","author":"Park","year":"2003","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.steroids.2013.01.008_b0145","first-page":"2537","article-title":"Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors","volume":"61","author":"Roger","year":"2001","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.steroids.2013.01.008_b0150","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/path.1436","article-title":"Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model","volume":"201","author":"Skliris","year":"2003","journal-title":"J Pathol"},{"issue":"9","key":"10.1016\/j.steroids.2013.01.008_b0155","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1210\/en.142.9.4120","article-title":"ER-beta inhibits proliferation and invasion of breast cancer cells","volume":"142","author":"Lazennec","year":"2001","journal-title":"Endocrinology"},{"issue":"1\u20133","key":"10.1016\/j.steroids.2013.01.008_b0160","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.febslet.2004.04.025","article-title":"Expression of estrogen receptor-beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis","volume":"566","author":"Cheng","year":"2004","journal-title":"FEBS Lett"},{"issue":"3","key":"10.1016\/j.steroids.2013.01.008_b0165","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1677\/JOE-07-0087","article-title":"Estrogen receptor \u2013 beta1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells","volume":"193","author":"Treeck","year":"2007","journal-title":"J Endocrinol"},{"issue":"2","key":"10.1016\/j.steroids.2013.01.008_b0170","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.canlet.2005.01.021","article-title":"Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis","volume":"231","author":"Lazennec","year":"2006","journal-title":"Cancer Lett"},{"issue":"27","key":"10.1016\/j.steroids.2013.01.008_b0175","doi-asserted-by":"crossref","first-page":"24353","DOI":"10.1074\/jbc.M201829200","article-title":"Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression","volume":"277","author":"Liu","year":"2002","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.steroids.2013.01.008_b0180","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1128\/MCB.17.7.4059","article-title":"Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution","volume":"17","author":"Planas-Silva","year":"1997","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.steroids.2013.01.008_b0185","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1006\/gyno.1996.4569","article-title":"Overexpression of cyclin D1 in epithelial ovarian cancers","volume":"64","author":"Worsley","year":"1997","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.steroids.2013.01.008_b0190","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/01.AOG.0000296715.07705.e9","article-title":"Estrogen receptor subtypes in ovarian cancer: a clinical correlation","volume":"111","author":"Chan","year":"2008","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.steroids.2013.01.008_b0195","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ygyno.2011.05.025","article-title":"Cytoplasmic expression of estrogen receptor beta (ER-beta) predicts poor clinical outcome in advanced serous ovarian cancer","volume":"122","author":"De Stefano","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"17","key":"10.1016\/j.steroids.2013.01.008_b0200","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1158\/1078-0432.CCR-04-0389","article-title":"Estrogen receptor beta (ER-beta) level but not its ER-beta cx variant helps to predict tamoxifen resistance in breast cancer","volume":"10","author":"Esslimani-Sahla","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.steroids.2013.01.008_b0205","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/jso.20336","article-title":"The changes of estrogen receptor-beta variants expression in breast carcinogenesis: decrease of estrogen receptor-beta2 expression is the key event in breast cancer development","volume":"93","author":"Park","year":"2006","journal-title":"J Surg Oncol"},{"issue":"12","key":"10.1016\/j.steroids.2013.01.008_b0210","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/j.1349-7006.2008.00988.x","article-title":"Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5\u2032-untranslated region in human epithelial ovarian carcinoma","volume":"99","author":"Suzuki","year":"2008","journal-title":"Cancer Sci"},{"issue":"35","key":"10.1016\/j.steroids.2013.01.008_b0215","doi-asserted-by":"crossref","first-page":"13162","DOI":"10.1073\/pnas.0605676103","article-title":"Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling","volume":"103","author":"Leung","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"48","key":"10.1016\/j.steroids.2013.01.008_b0220","doi-asserted-by":"crossref","first-page":"7600","DOI":"10.1038\/sj.onc.1207100","article-title":"Expression of estrogen receptor [beta] isoforms in normal breast epithelial cells and breast cancer: regulation by methylation","volume":"22","author":"Zhao","year":"2003","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.steroids.2013.01.008_b0225","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/S0002-9440(10)63760-1","article-title":"Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis","volume":"164","author":"Zhu","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.steroids.2013.01.008_b0230","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev.bi.63.070194.002315","article-title":"Molecular mechanisms of action of steroid\/thyroid receptor superfamily members","volume":"63","author":"Tsai","year":"1994","journal-title":"Annu Rev Biochem"},{"issue":"14","key":"10.1016\/j.steroids.2013.01.008_b0235","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1093\/nar\/29.14.2905","article-title":"Estrogen receptor interaction with estrogen response elements","volume":"29","author":"Klinge","year":"2001","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"10.1016\/j.steroids.2013.01.008_b0240","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1210\/me.2005-0334","article-title":"Estrogen receptor target gene: an evolving concept","volume":"20","author":"Carroll","year":"2006","journal-title":"Mol Endocrinol"},{"issue":"4","key":"10.1016\/j.steroids.2013.01.008_b0245","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1677\/erc.0.0030309","article-title":"Endocrine role in ovarian cancer","volume":"3","author":"Rao","year":"1996","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.steroids.2013.01.008_b0250","first-page":"1051","article-title":"Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the \u2018MALOVA\u2019 ovarian cancer study","volume":"18","author":"Hogdall","year":"2007","journal-title":"Oncol Rep"},{"issue":"3","key":"10.1016\/j.steroids.2013.01.008_b0255","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/modpathol.2010.211","article-title":"Molecular clustering based on ER[alpha] and EIG121 predicts survival in high-grade serous carcinoma of the ovary\/peritoneum","volume":"24","author":"Schlumbrecht","year":"2011","journal-title":"Mod Pathol"},{"issue":"24","key":"10.1016\/j.steroids.2013.01.008_b0260","doi-asserted-by":"crossref","first-page":"9243","DOI":"10.1073\/pnas.84.24.9243","article-title":"Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2","volume":"84","author":"Rio","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.steroids.2013.01.008_b0265","first-page":"955","article-title":"Estrogen-induced genes in breast cancer, and their medical importance","volume":"183","author":"Rochefort","year":"1999","journal-title":"Bull Acad Natl Med"},{"issue":"3","key":"10.1016\/j.steroids.2013.01.008_b0270","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1210\/er.20.3.253","article-title":"Tamoxifen, raloxifene, and the prevention of breast cancer","volume":"20","author":"Jordan","year":"1999","journal-title":"Endocr Rev"},{"issue":"1\u20135","key":"10.1016\/j.steroids.2013.01.008_b0275","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0960-0760(00)00142-4","article-title":"Estrogen regulated proteases and antiproteases in ovarian and breast cancer cells","volume":"76","author":"Rochefort","year":"2001","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"10.1016\/j.steroids.2013.01.008_b0280","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1158\/0008-5472.CAN-06-2909","article-title":"G Protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells","volume":"67","author":"Albanito","year":"2007","journal-title":"Cancer Res"},{"issue":"3\u20134","key":"10.1016\/j.steroids.2013.01.008_b0285","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0960-0760(97)00159-3","article-title":"Estrogen regulation of transforming growth factor-alpha in ovarian cancer","volume":"64","author":"Simpson","year":"1998","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"10.1016\/j.steroids.2013.01.008_b0290","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1210\/me.2002-0438","article-title":"Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells","volume":"17","author":"Hall","year":"2003","journal-title":"Mol Endocrinol"},{"issue":"1","key":"10.1016\/j.steroids.2013.01.008_b0295","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0303-7207(94)90140-6","article-title":"Transcriptional activation of c-myc proto-oncogene by estrogen in human ovarian cancer cells","volume":"99","author":"Chien","year":"1994","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"10.1016\/j.steroids.2013.01.008_b0300","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.onc.1205171","article-title":"Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells","volume":"21","author":"Moll","year":"2002","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.steroids.2013.01.008_b0305","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1073\/pnas.93.1.316","article-title":"Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells","volume":"93","author":"Clinton","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.steroids.2013.01.008_b0310","first-page":"2820","article-title":"Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting","volume":"63","author":"Kelley","year":"2003","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.steroids.2013.01.008_b0315","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/1097-0142(19910715)68:2<269::AID-CNCR2820680209>3.0.CO;2-O","article-title":"Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients","volume":"68","author":"Hatch","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.steroids.2013.01.008_b0320","first-page":"15","article-title":"Phase II trial of tamoxifen in patients with advanced epithelial ovarian cancer","author":"Gennatas","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.steroids.2013.01.008_b0325","series-title":"Ovarian cancer: the way ahead","first-page":"383","article-title":"Hormonal therapy of ovarian cancer","author":"Quinn","year":"1987"},{"issue":"4","key":"10.1016\/j.steroids.2013.01.008_b0330","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1046\/j.1525-1438.1995.05040301.x","article-title":"Tamoxifen in patients with advanced epithelial ovarian cancer","volume":"5","author":"Van Der Velden","year":"1995","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"10.1016\/j.steroids.2013.01.008_b0335","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1200\/JCO.1993.11.10.1957","article-title":"Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program","volume":"11","author":"Ahlgren","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.steroids.2013.01.008_b0340","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00713399","article-title":"Studies on the estrogen receptor in breast cancer \u2013 20years as a target for the treatment and prevention of cancer","volume":"36","author":"Jordan","year":"1995","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.steroids.2013.01.008_b0345","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/1097-0142(19890315)63:6<1074::AID-CNCR2820630606>3.0.CO;2-0","article-title":"Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial","volume":"63","author":"Schwartz","year":"1989","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.steroids.2013.01.008_b0350","first-page":"575","article-title":"Tamoxifen therapy of epithelial ovarian cancer","volume":"66","author":"Shirey","year":"1985","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.steroids.2013.01.008_b0355","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0090-8258(87)90294-0","article-title":"Tamoxifen therapy in recurrent epithelial ovarian carcinoma","volume":"27","author":"Weiner","year":"1987","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.steroids.2013.01.008_b0360","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ygyno.2010.08.002","volume":"119","author":"Hurteau","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.steroids.2013.01.008_b0365","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ygyno.2004.01.035","article-title":"Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer","volume":"93","author":"Markman","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.steroids.2013.01.008_b0370","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ygyno.2009.01.012","article-title":"A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer","volume":"113","author":"Argenta","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.steroids.2013.01.008_b0375","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jsbmb.2004.10.021","article-title":"Aromatase expression in ovarian epithelial cancers","volume":"93","author":"Cunat","year":"2005","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.steroids.2013.01.008_b0380","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1749-6632.1995.tb17369.x","article-title":"DHEA and peripheral androgen and estrogen formation: intracinology","volume":"774","author":"Labrie","year":"1995","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.steroids.2013.01.008_b0385","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/0090-8258(89)90607-0","article-title":"Importance of steroid receptors and aromatase activity in the prognosis of ovarian cancer: high tumor progesterone receptor levels correlate with longer survival","volume":"33","author":"Slotman","year":"1989","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.steroids.2013.01.008_b0390","first-page":"91","article-title":"Immunohistochemical localisation of aromatase and its correlation with progesterone receptors in ovarian epithelial tumours","volume":"16","author":"Kitawaki","year":"1996","journal-title":"Anticancer Res"},{"issue":"22","key":"10.1016\/j.steroids.2013.01.008_b0395","first-page":"6491","article-title":"Aromatization of testosterone by epithelial tumor cells cultured from patients with ovarian carcinoma","volume":"48","author":"Thompson","year":"1988","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.steroids.2013.01.008_b0400","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/sj.bjc.6601508","article-title":"First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?","volume":"90","author":"Wong","year":"2004","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.steroids.2013.01.008_b0405","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1677\/erc.0.0060197","article-title":"Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma","volume":"6","author":"Sasano","year":"1999","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"10.1016\/j.steroids.2013.01.008_b0410","first-page":"2233","article-title":"CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup","volume":"8","author":"Bowman","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.steroids.2013.01.008_b0415","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1158\/1078-0432.CCR-06-2878","article-title":"Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients","volume":"13","author":"Smyth","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.steroids.2013.01.008_b0610","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.5582","article-title":"Anti-tumor activity of letrozole in patients with recurrent advanced low malignant potential or low-grade serous ovarian tumors","volume":"25","author":"Kavanagh","year":"2007","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.steroids.2013.01.008_b0425","doi-asserted-by":"crossref","first-page":"9042","DOI":"10.1073\/pnas.160016897","article-title":"Down-regulation of p21WAF1\/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells","volume":"97","author":"Cariou","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.steroids.2013.01.008_b0430","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1210\/jc.2004-2456","article-title":"High-dose estrogen and clinical selective estrogen receptor modulators induce growth arrest, p21, and p53 in primate ovarian surface epithelial cells","volume":"90","author":"Wright","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.steroids.2013.01.008_b0435","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1158\/1078-0432.CCR-08-3127","article-title":"Combined src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors","volume":"15","author":"Chen","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2 Pt. 2","key":"10.1016\/j.steroids.2013.01.008_b0440","doi-asserted-by":"crossref","first-page":"865s","DOI":"10.1158\/1078-0432.865s.11.2","article-title":"Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer","volume":"11","author":"Osborne","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.steroids.2013.01.008_b0445","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2006.11.049","article-title":"P27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2","volume":"128","author":"Chu","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.steroids.2013.01.008_b0615","article-title":"Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo","author":"Chen","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"44","key":"10.1016\/j.steroids.2013.01.008_b0455","doi-asserted-by":"crossref","first-page":"40888","DOI":"10.1074\/jbc.M106448200","article-title":"Constitutive MEK\/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells","volume":"276","author":"Donovan","year":"2001","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.steroids.2013.01.008_b0460","first-page":"873","article-title":"Growth factor signaling in cell survival: implications for cancer treatment","volume":"298","author":"Talapatra","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.steroids.2013.01.008_b0465","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccr.2004.09.001","article-title":"C-Src and cooperating partners in human cancer","volume":"6","author":"Ishizawar","year":"2004","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.steroids.2013.01.008_b0470","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/gyno.2002.6851","article-title":"Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers","volume":"88","author":"Wiener","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"22","key":"10.1016\/j.steroids.2013.01.008_b0475","doi-asserted-by":"crossref","first-page":"10381","DOI":"10.1158\/0008-5472.CAN-05-1822","article-title":"SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells","volume":"65","author":"George","year":"2005","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.steroids.2013.01.008_b0480","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1158\/1535-7163.MCT-06-0401","article-title":"Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling","volume":"6","author":"Mullen","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1016\/j.steroids.2013.01.008_b0485","doi-asserted-by":"crossref","first-page":"11961","DOI":"10.1074\/jbc.M411985200","article-title":"Hyaluronan-CD44 interaction with IQGAP1 promotes Cdc42 and ERK signaling, leading to actin binding, Elk-1\/estrogen receptor transcriptional activation, and ovarian cancer progression","volume":"280","author":"Bourguignon","year":"2005","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.steroids.2013.01.008_b0490","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/carcin\/bgq276","article-title":"Estrogen receptor alpha pathway is involved in leptin-induced ovarian cancer cell growth","volume":"32","author":"Choi","year":"2011","journal-title":"Carcinogenesis"},{"issue":"40","key":"10.1016\/j.steroids.2013.01.008_b0495","doi-asserted-by":"crossref","first-page":"36869","DOI":"10.1074\/jbc.R100029200","article-title":"The multifaceted mechanisms of estradiol and estrogen receptor signaling","volume":"276","author":"Hall","year":"2001","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.steroids.2013.01.008_b0500","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF02685901","article-title":"The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer","volume":"24","author":"Karagol","year":"2007","journal-title":"Med Oncol"},{"issue":"7","key":"10.1016\/j.steroids.2013.01.008_b0505","first-page":"586","article-title":"Evaluation of efficacy and toxicity of tamoxifen in patients with advanced chemotherapy resistant ovarian cancer","volume":"69","author":"Rolski","year":"1998","journal-title":"Ginekol Pol"},{"key":"10.1016\/j.steroids.2013.01.008_b0510","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1046\/j.1525-1438.1997.00463.x","article-title":"Tamoxifen in the treatment of recurrent ovarian carcinoma","volume":"7","author":"Marth","year":"1997","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.steroids.2013.01.008_b0515","first-page":"2639","article-title":"A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer","volume":"15","author":"Jager","year":"1995","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.steroids.2013.01.008_b0520","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3109\/02841869509127191","article-title":"Experience with hormonal therapy in advanced epithelial ovarian cancer","volume":"34","author":"van der Vange","year":"1995","journal-title":"Acta Oncol"},{"issue":"Suppl. 1","key":"10.1016\/j.steroids.2013.01.008_b0525","first-page":"66","article-title":"Treatment of advanced ovarian cancer by hormone","volume":"3","author":"Losa","year":"1993","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.steroids.2013.01.008_b0530","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/bjc.1988.22","article-title":"Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule","volume":"57","author":"Osborne","year":"1988","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.steroids.2013.01.008_b0535","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0277-5379(86)90396-2","article-title":"A phase II study of tamoxifen in ovarian cancer","volume":"22","author":"Slevin","year":"1986","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.steroids.2013.01.008_b0620","first-page":"1059","article-title":"Antiestrogen as last-line treatment in epithelial ovarian cancer","volume":"4","author":"Landoni","year":"1985","journal-title":"Chemioterapia"},{"key":"10.1016\/j.steroids.2013.01.008_b0625","article-title":"Tamoxifen therapy in advanced ovarian cancer: a phase II study","volume":"4","author":"Hemerlynck","year":"1985","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.steroids.2013.01.008_b0550","first-page":"117","article-title":"Hormone receptors in ovarian carcinoma","volume":"4","author":"Rowland","year":"1985","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.steroids.2013.01.008_b0555","doi-asserted-by":"crossref","unstructured":"Pagel J, Rose CTS, Hald I. Treatment of advanced ovarian carcinoma with tamoxifen: a phase II trial. In: Proc 2nd Eur Conf, Clin Oncol; 1983.","DOI":"10.1016\/0022-4731(83)91716-8"},{"issue":"5","key":"10.1016\/j.steroids.2013.01.008_b0560","first-page":"583","article-title":"Tamoxifen therapy for advanced ovarian cancer","volume":"59","author":"Schwartz","year":"1982","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.steroids.2013.01.008_b0565","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ygyno.2008.03.014","article-title":"Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum","volume":"110","author":"Ramirez","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1016\/j.steroids.2013.01.008_b0570","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1158\/1078-0432.CCR-06-2878","article-title":"Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor positive patients","volume":"13","author":"Smyth","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.steroids.2013.01.008_b0630","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.5025","article-title":"Phase II study of letrozole in estrogen receptor (ER) positive relapsed epithelial ovarian cancer (EOC)","volume":"24","author":"Gourley","year":"2006","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.steroids.2013.01.008_b0580","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000077436","article-title":"Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study","volume":"66","author":"Papadimitriou","year":"2004","journal-title":"Oncology"},{"key":"10.1016\/j.steroids.2013.01.008_b0635","doi-asserted-by":"crossref","first-page":"5063","DOI":"10.1200\/jco.2005.23.16_suppl.5063","article-title":"Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian cancer","volume":"23","author":"Krasner","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.steroids.2013.01.008_b0590","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.ygyno.2003.08.021","article-title":"Phase II trial of anastrozole in women with asymptomatic mullerian cancer","volume":"91","author":"del Carmen","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.steroids.2013.01.008_b0640","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.5026","article-title":"Phase II study of exemestane (E) in refractory ovarian cancer (ROC)","volume":"24","author":"Verma","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X13000251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X13000251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T10:15:59Z","timestamp":1688033759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X13000251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":119,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0039128X13000251"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2013.01.008","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}